Human genome sciences reports initial results of randomized phase 2 trial of hgs-etr1 in combination with bortezomib in advanced multiple myeloma
September 6th, 2008 by 
admin Human Genome Sciences, Inc. (Nasdaq: HGSI) reportable initial topline results from an current irregular Phase 2 clinical effort of its TRAIL organ antibody HGS-ETR1 (mapatumumab) in compounding with bortezomib (Velcade) in patients with modern binary myeloma. The initial accumulation from the binary myeloma think exhibit that HGS-ETR1 was substantially tolerated and declare that disease salutation was same for this compounding vs. bortezomib alone. (Source: person / Oncology News From Medical News Today)
Tags: Cancer
Posted in Cancer | 